Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 88.17B, Moderna(MRNA) trades at $220.05. The stock has a price-to-earnings ratio of -27.77.
On 2026-11-02, Moderna(MRNA) stock traded between a low of $217.66 and a high of $230.52. Shares are currently priced at $220.05, which is +1.1% above the low and -4.5% below the high.
Moderna(MRNA) shares are trading with a volume of 8.44M, against a daily average of 18.98M.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $254.48 at its peak.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $254.48 at its peak.
MRNA News
Prediction markets are now listing odds on clinical outcomes for Moderna (NasdaqGS:MRNA), including its individualized melanoma vaccine. Public betting platfor...
...
The third-quarter 2026 reporting cycle for the Medical sector is in full swing, with most companies having already reported their results and several others sch...
Analyst ratings
56%
of 27 ratingsMore MRNA News
Moderna (MRNA -0.47%) has been the hottest stock in the S&P 500 this year, and it hasn't been close. Up around 650%, the next-best-performing stock is Sandisk,...
Moderna (MRNA -0.47%) stock, after a few years in the doldrums, has accomplished a major turnaround. The biotech company saw its stock soar in early pandemic da...
Merck and Moderna reported detailed Phase 3 INTerpath-001 data showing intismeran autogene plus KEYTRUDA cut recurrence or death risk by 42% and distant metasta...
It's not that rare to see stocks in the volatile biotech industry that quadruple (or more) in value over a relatively short period. That's what has happened to...
Merck and Moderna (NasdaqGS:MRNA) reported positive late-stage data for individualized mRNA melanoma therapy intismeran alongside standard treatment. The phase...
Moderna (MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new Phase 1 study titled “A Phase 1, Dose-escalation, Blinde...
Axsome Therapeutics: Steady and Consistent Revenue Growth Trends Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.